




Comprehensive T Cell Checkpoint Panel

In this Comprehensive T Cell Checkpoint Panel, Champions Oncology can interrogate multiple T Cell subset populations in PBMCs. This panel includes 19 colors and contains cell modulation components such as proliferation and activation markers, as well as clinical checkpoint inhibitor markers of interest. This panel also includes a Live/Dead staining component standard, which allows for clean separation of the subsets without risking dead cell contamination. Champions Oncology has the capacity to execute up to 24-color fully optimized and validated flow cytometry panels in one tube, therefore maximizing the value of your precious human clinical trial samples. In addition, this panel leaves 5 open channels available, to allow for customization with key markers.




Flow Cytometry Methodology


For this Comprehensive T Cell Checkpoint Panel, Champions Oncology scientists took PBMCs and either left unstimulated or stimulated with anti-CD3/CD28 at multiple timepoints to fully understand the temporal expression of each modulation marker of interest. At each timepoint, fluorescent antibodies were added to each sample and stained. A Live/Dead staining component was also used to discriminate dead cell contamination. Samples were collected on our BD Symphony instrument and analysis was completed using FlowJo Software.



Comprehensive T Cell Checkpoint Panel Gating Strategy



Time Course Analysis of Proliferation, Activation & Checkpoint Inhibitor Markers (3 samples were collected at each time point)



Each marker of interest was analyzed by timepoint to reveal the expression patterns for Ki-67 (cell proliferation), CD69 (cell activation) and Tim-3 (checkpoint inhibitor). As illustrated here, most markers are highly expressed between 48-72 hours.

Our scientific experts in flow cytometry can provide advice and guidance for all of your clinical trial needs. Please contact us to customize this panel for your upcoming clinical trials.